Suyu Liu

List of Publications by Year
in descending order

26 papers	1,538 citations	623734 14 h-index	713466 21 g-index
26 all docs	26 docs citations	26 times ranked	1889 citing authors

#	Article	IF	Citations
1	Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases. Clinical Lung Cancer, 2022, 23, 185-190.	2.6	3
2	Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics, 2022, 78, 60-71.	1.4	8
3	A randomized group sequential enrichment design for immunotherapy and targeted therapy. Contemporary Clinical Trials, 2022, , 106742.	1.8	1
4	Hybrid design evaluating new biomarkers when there is an existing screening test. Statistics in Medicine, 2021, 40, 2037-2054.	1.6	0
5	Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer. Cancer Prevention Research, 2021, 14, 729-740.	1.5	16
6	A Bayesian Phase I/II Design for Cancer Clinical Trials Combining an Immunotherapeutic Agent with a Chemotherapeutic Agent. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 1210-1229.	1.0	3
7	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discovery, 2021, 11, 2738-2747.	9.4	37
8	An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints. Biometrical Journal, 2020, 62, 339-349.	1.0	7
9	On the coherence of model-based dose-finding designs for drug combination trials. PLoS ONE, 2020, 15, e0242561.	2.5	2
10	On the coherence of model-based dose-finding designs for drug combination trials. , 2020, 15, e0242561.		0
11	On the coherence of model-based dose-finding designs for drug combination trials. , 2020, 15, e0242561.		0
12	On the coherence of model-based dose-finding designs for drug combination trials. , 2020, 15, e0242561.		0
13	On the coherence of model-based dose-finding designs for drug combination trials. , 2020, 15, e0242561.		0
14	A Utility-Based Bayesian Phase Iâ€“II Design for Immunotherapy Trials with Progression-Free Survival End Point. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 411-425.	1.0	13
15	A Bayesian Phase I/II Trial Design for Immunotherapy. Journal of the American Statistical Association, 2018, 113, 1016-1027.	3.1	38
16	A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	51
17	A robust Bayesian dose-finding design for phase I/II clinical trials. Biostatistics, 2016, 17, 249-263.	1.5	49
18	Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development. Statistics in Biosciences, 2016, 8, 99-128.	1.2	22

#	Article	IF	Citations
19	A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Statistics in Medicine, 2014, 33, 4017-4028.	1.6	26
20	Using Data Augmentation to Facilitate Conduct of Phase Iâ€“II Clinical Trials With Delayed Outcomes. Journal of the American Statistical Association, 2014, 109, 525-536.	3.1	86
21	Up-and-down designs for phase I clinical trials. Contemporary Clinical Trials, 2013, 36, 218-227.	1.8	24
22	A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities. Bayesian Analysis, 2013, 8, 703-722.	3.0	22
23	Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. Annals of Applied Statistics, 2013, 7, 1837-2457.	1.1	58
24	The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery, 2011, 1, 44-53.	9.4	778
25	Bayesian adaptive randomization designs for targeted agent development. Clinical Trials, 2010, 7, 584-596.	1.6	95
26	Bayesian adaptive design for targeted therapy development in lung cancer â€” a step toward personalized medicine. Clinical Trials, 2008, 5, 181-193.	1.6	199